Resistell AG closes CHF 3.5M series A financing round
Resistell AG has today closed an oversubscribed series A financing round led by OCCIDENT
. TRUMPF Venture
, Alpana Ventures
, Zürcher Kantonalbank
and seven private investors also back the start-up developing world’s fastest phenotypic antibiotic susceptibility test.
Antimicrobial resistance (AMR) is one of the biggest global health challenges today. The emergence of multi-drug resistant pathogens has made it increasingly difficult to choose the right antibiotic in time for critically ill patients. As a result, physicians are frequently turning to broad-spectrum antibiotics to reduce the risk of administering non-effective drugs. Excessive use of these powerful medicines then triggers the development of multi-drug resistance. Unless we can halt this trend, the world faces a death toll of up to 10 million people per year by 2050.
Read full article